This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Alunbrig click here.

Raising expectations in anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (aNSCLC) post crizotinib

Exceeds 1 year median PFSa in ALK+ aNSCLC patients post crizotinib1

ALUNBRIG is indicated as monotherapy for the treatment of adult patients with ALK+ aNSCLC previously treated with crizotinib1

a IRC and investigator assessed.

Tools and resources

Takeda Oncology has developed a range of tools and resources for HCPs and patients prescribed ALUNBRIG.

Click here to find out more

Patient support resources